Evidence map›Paper›PMID 32771429›Full record

ArticleJournal of hepatology2020

Reply to: Correspondence on "High rates of 30-day mortality in patients with cirrhosis and COVID-19".

Massimo Iavarone, Roberta D'Ambrosio, Pietro Lampertico, CirCoV study group

Registry-linked trialAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05204602 (Safety and Immunogenicity of Third Dose SARS-CoV-2 Vaccine Booster in Patients With Liver Diseases Following Two Doses of Inactivated Vaccines), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05204602 unknown statusnot on this mapstarted 2022, after this paper: background citation

Safety and Immunogenicity of Third Dose SARS-CoV-2 Vaccine Booster in Patients With Liver Diseases Following Two Doses of Inactivated Vaccines (NMCID-CHESS 2201): a Multicenter Cohort Study

TypeobservationalSponsorHuashan HospitalRan2022 to 2022Enrolled1,000ConditionsCOVID-19, Vaccine Reaction, Liver Diseases
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2021
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Massimo IavaroneFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy. Electronic address: massimo.iavarone@gmail.com.
Roberta D'AmbrosioFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy.
Pietro LamperticoFoundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, CRC "A. M. and A. Migliavacca" Center for Liver Disease, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
CirCoV study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularCOVID-19Liver NeoplasmsHumansLiver CirrhosisPandemicsSARS-CoV-2HBVHCVHepatitisHepatocellular carcinomaLiver transplantationSARS-CoV-2

Identifiers

PMID32771429
PMCPMC7410797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.